Resumo: |
Covid-19 pneumonia has poor prognosis in elderly patients. Mesenchymal stem cells (MSCs) transplantation is a last resource to treat COVID-19 SARS (ongoing clinical trials). Yet, differentiation ppluripotency and immunomodulatory properties decrease in aged MSCs, Scarcity of donors hampers the widespread use of allogenic MSCs. Based in our expertise, we aim at validating purinome-rejuvenated autologous MSCs transplantation as a viable therapeutic alternative against Covid-19 in aged patients. |